Typbar TCV – Bharat Biotech

Indication and Usage –

• Typbar-TCV can be administered to infants of age ≥6 months to ≤45 years, children and adults as a single dose.
• This is T-cell dependent which induces Vi antibodies that neutralize Vi antigen unlike T-cell independent plain Vi polysaccharide vaccines.
• The vaccine full fills WHO requirements for Typhoid Vi Conjugate vaccine.

Dosage and Administration –

• Typbar-TCV™ should be given intra muscularly in the deltoid or the vastus lateralis of subjects.
• The immunizing dose for adults, children and infants of age ≥6 months to ≤45 years is single dose of 0.5 mL; a booster dose may be given after 3 years.

Contraindications –

• Hypersensitivity to any constituent of the vaccine.
• Pregnant & lactating women.
• In the event of fever or severe infection.

 Adverse reactions –

• The most common general and local adverse events were fever (5-10%) and pain at injection site (2-3%) post vaccination. All these events were resolved within 48 hours with symptomatic treatment.
• Uncommon adverse events observed were itching, swelling, malaise and myalgia.

Drug interactions and other interactions –

• For concomitant or co-administration use different injection sites and separate syringes.
• Typbar-TCV should not be mixed with any other vaccine or medicinal product, because the interactions with other vaccines or medical products have not been established.
• Safety and effectiveness have not been established in pregnant women and in nursing mothers.

Frequently asked Questions and Answers:

1. What is TYPBAR-TCV and what is its use?
TYPBAR-TCV is a vaccine designed to prevent Typhoid, a bacterial infection caused by Salmonella typhi, a Gram-negative bacterium. Typhoid infection presents with symptoms such as prolonged high fever, fatigue, loss of appetite, abdominal pain, and a rash. It can lead to severe complications, including protracted fever lasting for weeks or even months. While Typhoid can be treated with antibiotics, rising antibiotic resistance complicates its management. However, immunization can effectively prevent Typhoid. Clinical studies have demonstrated that TYPBAR-TCV is well-tolerated and highly effective for individuals aged 6 months to 45 years.

2. Key Considerations Before Administering TYPBAR-TCV
Inform doctor before getting vaccinated with TYPBAR if:

• The individual has a history of allergic reactions to the typhoid vaccine or any of its components
• The individual is currently ill
• The individual is taking antibiotics
• The individual has a weakened immune system due to conditions such as HIV/AIDS, cancer, or medications that affect the immune system

3. How is TYPBAR-TCV administered?
TYPBAR-TCV is administered through intramuscular injection. For infants aged ≤12 months, the injection should be given in the vastus lateralis muscle (anterolateral aspect of the thigh), while for children aged ≥12 months and adults, it should be administered in the deltoid muscle (upper arm). A single dose of any Typhoid conjugate vaccine is recommended for individuals aged 6 months and older.

4. What are the common side effects after TYPBAR-TCV administration?
Common side effects of the Typhoid vaccine may include pain, redness, or swelling at the injection site, fever, headache, and muscle pain.